How Large-Volume Electroporation Is Powering the Next Phase of Cell Therapy

Published on Lonza Overview (CT-SP019)

Scaling cell therapy from benchtop to bedside requires technologies that are efficient, compliant, and clinically proven. Lonza’s 4D-Nucleofector® LV Unit is featured in several preclinical and clinical studies for non-viral delivery of gene-editing tools like CRISPR, base editors, and mRNA. The poster highlights use cases from leukemia and sickle cell disease to synthetic virus production, demonstrating scalable transfection of up to 2 billion cells. These applications underscore the unit’s growing relevance in large-batch CAR-T, TCR, and HSC manufacturing pipelines.

Read the full summary on Lonza:

👉 Large-volume non-viral genetic modification using the 4D-Nucleofector LV Unit (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.